Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical.

Similar presentations


Presentation on theme: "Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical."— Presentation transcript:

1 Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results  Jeffrey M. Isner, MD, Iris Baumgartner, MD, Guenter Rauh, MD, Robert Schainfeld, DO, Richard Blair, MD, Orit Manor, MD, Syed Razvi, MD, James F. Symes, MD  Journal of Vascular Surgery  Volume 28, Issue 6, Pages (December 1998) DOI: /S (98) Copyright © 1998 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

2 Fig. 1 Toe plethysmographic tracings taken from a patient immediately before and 4 weeks after initial treatment with VEGF165 gene therapy. Journal of Vascular Surgery  , DOI: ( /S (98) ) Copyright © 1998 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

3 Fig. 2 Digital subtraction angiogram from a patient before gene therapy showing typical findings of Buerger's disease at distal popliteal and tibial levels with normal femoral vessel proximally. Angiogram after gene therapy at 8 weeks shows significant increase in collateral formation. Journal of Vascular Surgery  , DOI: ( /S (98) ) Copyright © 1998 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

4 Fig. 3 Magnetic resonance angiograms without intravenous contrast medium from a patient before and after gene therapy illustrating both increased number of collateral vessels and increased signal intensity in previously identified vessels. Journal of Vascular Surgery  , DOI: ( /S (98) ) Copyright © 1998 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

5 Fig. 4 Photographs of feet of 2 patients showing healing of necrotic lesions of toes 6 to 8 weeks after initiation of gene therapy with phVEGF165. Journal of Vascular Surgery  , DOI: ( /S (98) ) Copyright © 1998 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

6 Fig. 5 Representative histologic sections of tissue retrieved from a patient with Buerger's disease at time of limb amputation. Serial sections stained with elastic tissue trichrome (left) and hematoxylin and eosin (middle) show small arteries and veins containing thrombus and surrounded by significant inflammatory cell infiltrate. Note preservation of normal blood vessel architecture. Photomicrograph on right is a higher magnification of area indicated in middle photo. Journal of Vascular Surgery  , DOI: ( /S (98) ) Copyright © 1998 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions


Download ppt "Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical."

Similar presentations


Ads by Google